MRSA Clinical Trial
Official title:
Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients
Staphylococcus aureus (S. aureus) is a leading cause of healthcare-associated infections worldwide. S. aureus colonizes several body sites, including the nose, throat, and perineum. Colonization by methicillin-resistant S. aureus (MRSA) increases the risk of infection by up to 27%, with infecting strains matching colonizing strains in up to 86% of cases. Decolonization, the goal of which is to decrease or eliminate bacterial load on the body, is an integral part of the strategies used to control and prevent the spread of MRSA. This approach involves eradication of MRSA carriage from the nose through the intranasal application of an antimicrobial agent and body washes with an antiseptic soap to eliminate bacteria from other body sites. The most commonly used agents for MRSA decolonization are intranasal mupirocin ointment applied to the anterior nares and chlorhexidine body wash. Postdischarge MRSA decolonization with chlorhexidine and mupirocin led to a 30% lower risk of MRSA infection. However, there are growing concerns about decolonization failures following the emergence of mupirocin and chlorhexidine resistance. Povidone iodine (PVP-I) is an alternative decolonization agent solutions and demonstrated rapid and superior bactericidal activity against MRSA in in vitro and ex vivo studies available reports. Finally, the induction of bacterial resistance or cross-resistance to antiseptics and antibiotics with PVP-I was not observed. The present protocol aims to use a "Decolonization kit" into MRSA patients to evaluate the efficacy of MRSA nasal decolonization with a topical PVP-I gel. This kit will allow a complete transient decolonization with povidone-iodine (PVP-I)-based products: nasal (gel), body (antiseptic soap) and oral (mouthwash).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03181932 -
AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
|
Phase 3 | |
| Completed |
NCT03268122 -
Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE
|
N/A | |
| Completed |
NCT04312776 -
Tracing MRSA in Households With Patients Infected With CA-MRSA by WGS
|
||
| Recruiting |
NCT04104178 -
Optimal Treatment of MRSA Throat Carriers
|
Phase 3 | |
| Recruiting |
NCT04793152 -
Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC
|
N/A | |
| Completed |
NCT03601741 -
Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination
|
N/A | |
| Completed |
NCT02690415 -
Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses
|
||
| Enrolling by invitation |
NCT04297592 -
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
|
Phase 4 | |
| Recruiting |
NCT05268120 -
MRSA Decolonization in Complicated Carriage
|
N/A | |
| Completed |
NCT01167452 -
Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations
|
Phase 4 | |
| Recruiting |
NCT04083092 -
Surveillance of Community-Associated MRSA
|
||
| Recruiting |
NCT02443064 -
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
|
Phase 4 | |
| Completed |
NCT02029872 -
Stop Community MRSA Colonization Among Patients
|
Phase 4 | |
| Recruiting |
NCT02127658 -
MRSA Eradication and Decolonization in Children
|
N/A | |
| Completed |
NCT00822276 -
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
|
N/A | |
| Withdrawn |
NCT02547116 -
Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
|
Phase 4 | |
| Completed |
NCT01318213 -
Benefits of Universal Glove and Gowning
|
||
| Completed |
NCT03304873 -
Retapamulin as a Decolonizing Agent for MRSA
|
Phase 3 | |
| Enrolling by invitation |
NCT05395520 -
Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections?
|